It is well established that muramyl dipeptide (MDP) can induce fever and enhance slow-wave sleep. Recently, crude or purified supernatants of activated macrophages containing endogenous pyrogen (EP) were also shown to enhance slow-wave sleep. These similarities and the recent finding that a mammalian factor that enhances slow-wave sleep is a muramyl peptide triggered us to study the possibility of the presence of this bacterial structure in the EP molecule. In the present study, EP was produced by stimulation of rabbit peritoneal cells with a nonpyrogenic, nonsomnogenic analog of MDP, The EP-containing supernatant lost its pyrogenicity and somnogenicity after passage over an immunoadsorbent column of monoclonal anti-MDP but not of another monoclonal antibody of different specificity. High percentage of the EP was recovered by elution of the anti-MDP columns with HCI/glycine buffer. Results suggest that bacterial muramyl peptides may be incorporated by mammalian cells into substances that act in picomole quantities to mediate immunological and physiological processes. In addition, the technique may be useful to extract interleukin 1 for structural studies.
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A sleep-promoting factor in cerebrospinal fluid from sleepdeprived goats was described by Pappenheimer and colleagues >15 yr ago (1, 2) . More recently, a muramyl peptide having sleep-promoting properties, similar to the cerebrospinal fluid factor, was isolated from brains of sleep-deprived rabbits and from human urine (3) . The active factor(s) from each of these sources specifically enhanced slow-wave sleep (SWS) in rats, rabbits, and cats. Synthetic muramyl dipeptide (MDP) and several of its adjuvant-active analogs were also shown to enhance SWS (4, 5) . The somnogenic muramyl peptides, natural or synthetic, were also pyrogenic and it was shown that a pyrogenic purified interleukin 1 (IL-1) is strongly somnogenic (6) . A close relationship between endogenous pyrogen (EP), sometimes designated by IL-1, and muramyl peptides was revealed by monoclonal antibodies raised against MDP: these antibodies bound to sleep-promoting factor purified from urine or brain, and they also inhibited the IL-1 enhancement of phytohemagglutinin-induced thymocyte proliferation (7) .
We now describe preparation of an immunoadsorbent column (UAG) of monoclonal anti-MDP antibody that specifically binds the pyrogenic and somnogenic activities contained in supernatants of activated rabbit macrophages. The active factor, presumably IL-1, can be eluted in high yield by HCl/glycine buffer. These experiments provide evidence that endogenous pyrogen (IL-1) contains an MDP-like structure or binds nonspecifically to MDP. In either case, the IAC itself may be used to prepare relatively large quantities of highly purified IL-1 for structural studies. MDP it has no pyrogenic or somnogenic actions (5, 9) . Murabutide reacts with antibody to MDP but does not stimulate EP production and has no pyrogenic or somnogenic effects (9, 10) .
MATERIALS AND METHODS
Monoclonal Antibodies. The preparation and characterization of monoclonal anti-MDP antibodies has been described elsewhere (11) . In this study, two such monoclonal antibodies were used-namely, 2-4-5 (IgG3) and M-52-11 (IgG2a). By using the previously described ELISA for detection of specificity, both monoclonal antibodies were found to bind to MDP and were not capable of recognizing either the sugar (N-acetylmuramic acid) or the dipeptide (L-Ala-n-isoGln) separately. Monoclonal anti-dinitrophenyl (DNP) antibody (namely, U-7-27), prepared as described (12) , was used as a control and was kindly provided by Z. Eshhar (Weizmann Institute of Sciences, Israel). In some, experiments, immunoglobulin fractions (50% ammonium sulfate precipitation) of ascitic fluid were used in the preparation of IAC. In other experiments, an IgG fraction of ascitic immunoglobulin isolated on Sephacryl S-200 column (Pharmacia) was used in the preparation of the IAC.
Preparation of IAC. This was carried out according to the manufacturer's instructions. Briefly, cyanogen bromide-activated Sepharose 4B (Pharmacia) was washed on sintered glass filters (G3) with 1 mM hydrochloric acid. The gel was immediately mixed with monoclonal antibody (either as ascitic immunoglobulin or as IgG fraction) dissolved in 0.1 M sodium bicarbonate buffer (pH 8.3) containing 0.5 M sodium chloride (referred to as coupling buffer) at a ratio of 5 mg of protein per ml of gel. The coupling step was carried out overnight at 40C with gentle end-over-end mixing. The amount of protein coupled on the gel was in all cases >90% of the total protein added, as determined spectrophotometrically at 280 nm. After washing uncoupled protein from the resin, the remaining active groups on the gel were blocked by mixing the Abbreviations: DNP, dinitrophenyl; EP, endogenovs pyrogen; IAC, immunoadsorbent columns; i.c.v., intracerebroventricular; IL-1, interleukin 1; MDP, muramyl dipeptide for N-acetylmuramyl-L-alanyl-D-isoglutamine; PEC, peritoneal exudate cells; SWS, slow-wave sleep.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. gel with 0.2 M glycine (pH 8.0) for 2 hr at room temperature. The gel was further washed 5 times alternately with coupling buffer followed by acetate buffer (0.1 M; pH 4.0) to remove adsorbed protein. It was then poured into a 10-ml syringe or a C 10/10 Pharmacia column and washed extensively with pyrogen-free phosphate-buffered saline (pH 7.4). Nonspecific protein binding was further blocked by passing 20 mg of bovine serum albumin over each column, followed by washing with buffer, and eluting with 0.1 M glycine/HCI, pH 2.8. The columns were then equilibrated with phosphate-buffered saline (pH 7.4) before applying the active peritoneal exudate cell (PEC) supernatants. The flow rate was 0.5 ml/min for packing, 0.2 ml/min for sample passage, and 0.5 ml/min for elution.
Preparation of Cell Supernatants. Adherent cells from rabbit peritoneal exudate (107 per ml) were cultured under conditions reported elsewhere (13) . Briefly, they were incubated for 18 hr with 100 ,ug of murametide per ml or other MDP analogs in serum-free medium and then dialyzed overnight against buffer to remove low-molecular-weight glycopeptides.
Rabbit Pyrogen Assay. New Zealand White male rabbits (2.5-3.5 kg) were used throughout the study. All glassware, needles, and syringes, and phosphate-buffered saline were pyrogen-free. Injections were made via the marginal ear vein (i.v.) or through the cannula (20 ,ul/kg) inserted into the lateral ventricle (intracerebroventricular, i.c.v.) according to procedures previously described (14) . Table 1 as maximum change in temperature after i.v. injection (At0C SD). The pyrogenic a,-tivity was retained on the anti-MDP columns (M-52-11 and 2-4-5). In contrast, no apparent loss of pyrogenic activity was observed after passage of supernatant over ajiti-DNP column (U-7-27). Moreover, after being blocked by murabutide the anti-MDP IAC no longer retained pyrogenicity, indicating that this retention was specific.
Elution of EP from Monoclonal Anti-MDP IAC. In the following experiment, another murametide-treated PEC supernatant was passed under the same conditions on IAC of IgG fraction from ascitic immunoglobulin of either U-7-27 (anti-DNP) or of M-52-11 (anti-MDP). After collecting the first eluate as described above in a final vol of 20 ml, each column was washed with 10 ml of buffer then eluted with 20 ml of 0.1 M glycine/HCI, pH 2.8. The pH of the eluate was neutralized to 7.0 with 1 M Tris HCl and the eluate was concentrated 4-fold by using an immersible ultrafiltration unit (Millipore), to a vol of 5 ml in preparation for the biological assay.
In this case, to evaluate pyrogenic activity in different eluates, the i.c.v. route was used. This route is much more sensitive, because the minimal pyrogenic dose is -0.2 ul/kg instead of 0.5 ml/kg after i.v. administration. Changes in temperature after i.c.v. administration of the eluates of each column, as well as of the supernatant before passage over the columns, are reported in Table 2 . The minimal pyrogenic dose of the murametide-treated PEC supernatant before passage through the columns was <0.3 ul/kg. In contrast, even at 2.5 pl/kg the eluate of the anti-DNP column was not pyrogenic. However, pyrogenic activity was present in the eluate of the anti-MDP column. In this case, a dose of 0.3 pul/kg was sufficient to induce febrile responses, and 0.6 pl1/kg gave the same increase in temperature as 0.3 pl/kg of the control supernatant, suggesting that -50% of the activity has been recovered. (6) . We assayed, therefore, for somnogenic and pyrogenic activities of PEC supernatants before and after passage through IACs. Furthermore, eluates of anti-DNP (U-7-27) or anti-MDP (M-52-11) IACs were checked for these activities. Results presented in Table 3 (mean of two separate experiments with different supernatants and different IACs) show that the pyrogenic supernatants were also somnogenic. After passage over an anti-DNP IAC, neither of these activities was lost. In contrast, both activities were retained on the IAC of monoclonal anti-MDP antibody. Moreover, both somnogenicity and pyrogenicity were demonstrated in the eluates of the anti-MDP but not in the eluates of the anti-DNP IAC (Table 3) .
DISCUSSION
The study reported here was carried out in view of two purposes: (i) a possible procedure to extract and purify IL-1, and (ii) pursuing previous experiments that suggested an MDP-like structure in mammalian mediators. Early attempts to purify IL-1 have been unsatisfactory: at best, very low yields were obtained (15) (16) (17) . The possibility of using lACs has recently been explored by Mizel et al. (18) , who used polyclonal antibodies raised in goats against purified supernatants containing IL-1. In the present investigation, we have observed high yields of IL-1 by using an IAC prepared with a monoclonal antibody to MDP. The specificity of absorption was demonstrated by lack of retention of EP over an IAC of the same monoclonal antibody blocked with another nonpyrogenic MDP derivative (murabutide). However, our results do not exclude the possibility of nonspecific absorption of murametide to the generated IL-1 in cultures. The monokine could then be absorbed on the IAC of monoclonal anti-MDP by virtue of the attached murametide and not because of specific recognition of IL-1. In any case, it appears likely, therefore, that this technique can be developed to obtain highly purified IL-1 in quantities required for structural studies. Whether an MDP-like structure of the same or of different configuration also exists in supernatants of other IL-1-producing cells activated by MDP or by other immunostimulants still remains to be elucidated.
MDP and several of its analogs have a large spectrum of activities (19, 20) , some of which could be related to the central nervous system (5, 14) . Thus, in addition to being immunoadjuvants, they are capable, like many other bacterial products, of producing hyperthermia and of inducing in vivo and in vitro EP (21, 22) . More recently, a factor that increases SWS was shown to be a low-molecular-weight muramyl peptide, containing muramic and diaminopimelic acids.
Moreover, similarities in the biological activities between MDP and IL-1 have well been noted: both molecules are known to be pyrogenic (14, 21) , somnogenic (5, 6) , to possess adjuvant activity (23, 24) , regulate T-cell activity (25) (26) (27) , induce serum amyloid A protein (28, 29) , and increase the production of prostaglandin E2 and collagenase (30, 31) .
These similarities and other observations suggesting the presence of an MDP-like structure in IL-1 led us to propose that the host is capable of using, as biological mediators (20) , bacterial products coupled to natural amino acids after degradation in the macrophage or other phagocytic cells. It is known that bacterial peptidoglycans, be they living microorganisms or bacterial debris, are continually engulfed by the reticuloendothelial system; digestion end-products include muramyl peptides (32) . Thus, muramyl peptides are available to mammalian tissues. Furthermore, muramic acid in hydrolyzable linkage is found in normal mammalian tissue (33) and normal mammalian urine contains diaminopimelic acid (34) . The arguments in favor of an MDP-like structure in monokines can be summarized as follows: (i) crude or purified supernatant of activated macrophages elicits fever and can also increase SWS; (ii) several synthetic muramyl peptides were found to be both pyrogenic and somnogenic; (iii) a monoclonal anti-MDP antibody that recognizes the overall MDP molecule, but neither the sugar nor the dipeptide separately, can bind to urinary or brain purified factor, which enhances SWS; (iv) this same monoclonal antibody was also shown to specifically inhibit the biological activity of a purified monokine. Our present results of absorbing specifically and recovering EP using monoclonal anti-MDP antibodies provide further evidence in favor of this hypothesis. Recent findings indicate that messenger molecules found in microbes could indeed be the ancestors of several vertebrate hormones and other mediators (35) . However, these messengers contained amino acids known to be normally involved in mammalian metabolism.
It has been suggested that several of the immunologic activities of muramyl peptides could be due to biological mimicry with endogenous products (36) somewhat like morphine-endorphine. However, like morphine, muramic acid is not a normal constituent of mammalian tissue. It is possible, therefore, that instead of being a copy of an endogenous product, muramyl peptides could be biological agents used by the host as a vitamin (37)-i.e., exogenous products that (8) 0.65 ± 0.07 (2) Exp, experimental. Number of rabbits is given in parentheses. For % SWS data, the same rabbits were used before and after injection.
*% SWS during a 6 hr post-infusion period of 20 1.l of sample. tMaximum change in temperature after i.v. injection of sample at 0.5 ml/kg. tSignificant difference from control, P < 0.05. Each rabbit was its own control; paired statistics were used. the host requires but cannot synthesize. Recognition of anti-MDP monoclonal antibodies of mediators capable of enhancing SWS as well as of eliciting fever strongly supports this view.
